Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CA052-002  |   NCT04895709

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Summary

  • Phase 1/Phase 2
  • Male and Female Gender icon
  • 18+
    Age Range
  • 38
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
  • Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis.
    1. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable.
      1. Eastern Cooperative Oncology Group Performance Status of 0 or 1.
        1. Radiographically documented progressive disease on or after the most recent therapy.
          1. Received standard-of-care therapies, (except for Part 1C, 2C and 2D, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated.
            1. Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant.

              Exclusion Criteria

              Exclusion Criteria Icon
              • Women who are pregnant or breastfeeding.
                1. Primary central nervous system (CNS) malignancy.
                  1. Untreated CNS metastases.
                    1. Leptomeningeal metastases.
                      1. Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment.
                        1. Active, known, or suspected autoimmune disease.
                          1. Condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment.
                            1. Prior organ or tissue allograft.
                              1. Uncontrolled or significant cardiovascular disease.
                                1. Major surgery within 4 weeks of study drug administration.
                                  1. History of or with active interstitial lung disease or pulmonary fibrosis.
                                    1. Other protocol-defined inclusion/exclusion criteria apply.
                                      Additional Information *

                                      Treatment Options

                                      Study Arms

                                      ASSIGNED INTERVENTION

                                      Study Arms

                                      Experimental: Part 1A-J: BMS-986340 Dose Escalation

                                      ASSIGNED INTERVENTION
                                      • Drug: BMS-986340

                                      Study Arms

                                      Experimental: Part 1A: BMS-986340 Dose Escalation

                                      ASSIGNED INTERVENTION
                                      • Drug: BMS-986340

                                      Study Arms

                                      Experimental: Part 1B-J: BMS-986340 + Nivolumab Dose Escalation

                                      ASSIGNED INTERVENTION
                                      • Drug: BMS-986340, BMS-936558-01

                                      Study Arms

                                      Experimental: Part 1B: BMS-986340 + Nivolumab Dose Escalation

                                      ASSIGNED INTERVENTION
                                      • Drug: BMS-986340, BMS-936558-01

                                      Study Arms

                                      Experimental: Part 1C: BMS-986340 + Docetaxel Dose Escalation

                                      ASSIGNED INTERVENTION
                                      • Drug: BMS-986340, Docetaxel

                                      Study Arms

                                      Experimental: Part 2A: BMS-986340 Dose Expansion

                                      ASSIGNED INTERVENTION
                                      • Drug: BMS-986340

                                      Study Arms

                                      Experimental: Part 2B: BMS-986340 + Nivolumab Dose Expansion

                                      ASSIGNED INTERVENTION
                                      • Drug: BMS-986340, BMS-936558-01

                                      Study Arms

                                      Experimental: Part 2C: BMS-986340 + Docetaxel Dose Expansion

                                      ASSIGNED INTERVENTION
                                      • Drug: BMS-986340, Docetaxel

                                      Study Arms

                                      Experimental: Part 2D: BMS-986340 + Pumitamig Dose Expansion

                                      ASSIGNED INTERVENTION
                                      • Drug: Pumitamig, BMS-986340
                                      Please select a study site to register
                                      Select a Study Site Location
                                      Select a study site location that is convenient for you
                                      Register
                                      Provide your contact details for the study site to connect with you.

                                      Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you